Analysis of BRAF mutation in primary and metastatic melanoma - PubMed (original) (raw)
Analysis of BRAF mutation in primary and metastatic melanoma
Massimo Libra et al. Cell Cycle. 2005 Oct.
Abstract
Mutation of BRAF has been proposed to contribute to melanoma development. However, it remains unclear whether or not BRAF mutation is associated with any particular stage of melanoma progression. Tumor biopsy specimens from patients with melanoma were analyzed to determine whether the frequency of BRAF mutation in metastatic melanoma differed from primary melanoma. BRAF mutation was present in 15 of 23 (61%) patients with primary melanoma and in 7 of 12 (58%) patients with metastatic melanoma. These results suggest that BRAF mutation in melanoma is most likely to occur prior to the development of metastatic disease.
Similar articles
- Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I, Marks L, Kerick M, Klages S, Berking C, Herbst R, Völker B, Schacht V, Timmermann B, Gutzmer R. Satzger I, et al. Oncotarget. 2015 Nov 10;6(35):37895-905. doi: 10.18632/oncotarget.5634. Oncotarget. 2015. PMID: 26498143 Free PMC article. - Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
Saroufim M, Habib RH, Gerges R, Saab J, Loya A, Amr SS, Sheikh S, Satti M, Oberkanins C, Khalifeh I. Saroufim M, et al. Exp Mol Pathol. 2014 Dec;97(3):315-20. doi: 10.1016/j.yexmp.2014.09.008. Epub 2014 Sep 16. Exp Mol Pathol. 2014. PMID: 25236573 - Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.
Hofman V, Ilie M, Long-Mira E, Giacchero D, Butori C, Dadone B, Selva E, Tanga V, Passeron T, Poissonnet G, Emile JF, Lacour JP, Bahadoran P, Hofman P. Hofman V, et al. J Invest Dermatol. 2013 May;133(5):1378-81. doi: 10.1038/jid.2012.485. Epub 2013 Jan 10. J Invest Dermatol. 2013. PMID: 23303445 No abstract available. - Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients.
Saint-Jean M, Quereux G, Nguyen JM, Peuvrel L, Brocard A, Vallee A, Knol AC, Khammari A, Denis MG, Dréno B. Saint-Jean M, et al. Oncol Rep. 2014 Aug;32(2):808-14. doi: 10.3892/or.2014.3265. Epub 2014 Jun 13. Oncol Rep. 2014. PMID: 24926836 - Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis.
Valachis A, Ullenhag GJ. Valachis A, et al. Eur J Cancer. 2017 Aug;81:106-115. doi: 10.1016/j.ejca.2017.05.015. Epub 2017 Jun 15. Eur J Cancer. 2017. PMID: 28623774 Review.
Cited by
- Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.
Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB. Puzanov I, et al. Eur J Cancer. 2015 Jul;51(11):1435-43. doi: 10.1016/j.ejca.2015.04.010. Epub 2015 May 13. Eur J Cancer. 2015. PMID: 25980594 Free PMC article. Clinical Trial. - Melanoma: from mutations to medicine.
Tsao H, Chin L, Garraway LA, Fisher DE. Tsao H, et al. Genes Dev. 2012 Jun 1;26(11):1131-55. doi: 10.1101/gad.191999.112. Genes Dev. 2012. PMID: 22661227 Free PMC article. Review. - Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma.
Zhou L, Yang K, Andl T, Wickett RR, Zhang Y. Zhou L, et al. J Cancer. 2015 Jun 23;6(8):717-26. doi: 10.7150/jca.10865. eCollection 2015. J Cancer. 2015. PMID: 26185533 Free PMC article. Review. - Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
McArthur GA, Mohr P, Ascierto PA, Arance A, Banos Hernaez A, Kaskel P, Weichenthal M, Shinde R, Stevinson K. McArthur GA, et al. Oncologist. 2017 Aug;22(8):951-962. doi: 10.1634/theoncologist.2016-0272. Epub 2017 May 19. Oncologist. 2017. PMID: 28526721 Free PMC article. - Targeting the ERK Signaling Pathway in Melanoma.
Savoia P, Fava P, Casoni F, Cremona O. Savoia P, et al. Int J Mol Sci. 2019 Mar 25;20(6):1483. doi: 10.3390/ijms20061483. Int J Mol Sci. 2019. PMID: 30934534 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials